Biogen (BIIB) Earnings Date & Reports

Key Takeaways

• Biogen reported total revenue of $2.80 billion for the third quarter, up 11% year over year and above consensus estimates of roughly $2.64 billion.
• Adjusted (non-GAAP) earnings per share came in at $2.62, comfortably beating analyst expectations of about $2.02, while GAAP results slipped to a net loss of $0.14 per share on transaction-related charges.
• The Growth Portfolio generated $1.26 billion in revenue, up 49% year over year, and now represents roughly 63% of core pharmaceutical revenue.
• Biogen raised the lower end of its full-year 2026 adjusted earnings per share guidance to a range of $12.20 to $13.00, reflecting business strength and favorable Apellis-related dilution.
• Multiple sclerosis product revenue declined 13% to $919 million, underscoring continued competitive pressure on the company's legacy franchise.
• For more information on the ticker's Major News, Today's Price Move, Price Targets, and Forecast, explore these dedicated pages.
• Discover additional market opportunities by exploring Trending AI Robots.

Earnings Context and Why It Matters

Biogen's third-quarter results mark a pivotal checkpoint in the company's ongoing effort to pivot away from its aging multiple sclerosis franchise and toward a diversified growth portfolio spanning neurology, rare disease, and immunology. This quarter included the first full three-month contribution from SYFOVRE and EMPAVELI, acquired through the Apellis transaction completed in May 2026. Investors have been closely watching whether these newer products can offset persistent declines in legacy treatments such as TECFIDERA and VUMERITY. The report also carried heightened significance because of Biogen's near-term clinical catalysts, with pivotal late-stage readouts expected in the coming months. A return to double-digit revenue growth signals that the strategic transition is gaining traction, even as elevated research spending and acquisition-related charges weigh on reported profitability.

Reported Results

Biogen posted third-quarter total revenue of $2.80 billion, an 11% increase from $2.53 billion in the prior-year period and ahead of analyst forecasts. Adjusted earnings per share (EPS) reached $2.62, exceeding the consensus estimate of roughly $2.02, though it declined from $4.81 a year earlier. On a generally accepted accounting principles (GAAP) basis, the company recorded a net loss of $20.6 million, or $0.14 per share, compared with net income of $466.5 million, or $3.17 per share, a year ago. The swing to a GAAP loss primarily reflected $284 million in acquired in-process research and development (IPR&D) charges tied to the RayThera acquisition, along with amortization and restructuring costs.

The Growth Portfolio delivered $1.26 billion in revenue, up 49% year over year. SPINRAZA rose 23% to $461 million, LEQEMBI climbed 67% to $202 million, and SKYCLARYS advanced 34% to $178 million. The newly acquired Apellis products contributed a combined $243 million, with SYFOVRE recording $191 million and EMPAVELI $52 million. Rare disease revenue increased 27% to $676 million, while multiple sclerosis product revenue fell 13% to $919 million. Biogen also raised the lower end of its full-year 2026 adjusted EPS guidance to $12.20, maintaining the upper end at $13.00, and reaffirmed expectations for mid-single-digit full-year revenue growth.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities far more efficiently than manual screening. For investors monitoring names like Biogen and the broader biotechnology sector, the AI Screener offers a structured way to surface potential setups and compare opportunities across the market.

Market Reaction and Investor Sentiment

Sentiment around Biogen's report centered on the strength of the top-line beat and the upward revision to full-year earnings guidance, which suggested that the company's growth portfolio is scaling faster than anticipated. The first full-quarter contribution from SYFOVRE and EMPAVELI reinforced confidence that the Apellis integration is progressing well, with management indicating the deal is now roughly neutral on an operating basis. Still, the GAAP loss and a 13% decline in the legacy multiple sclerosis franchise tempered some enthusiasm, reminding investors that the company's transformation is not yet complete. Looking ahead, market attention is shifting to a series of late-stage clinical readouts expected over the next several months, which could act as more significant catalysts for the stock than the quarterly figures themselves.

Forward Outlook and Key Factors to Monitor

Biogen's near-term narrative now hinges on its registrational readout cycle. The company expects to announce top-line data from the TOPAZ-1 and TOPAZ-2 Phase 3 studies of litifilimab in systemic lupus erythematosus (SLE) in the first half of December 2026. Positive results could materially expand Biogen's immunology franchise and reinforce its diversification strategy.

Beyond that, additional Phase 3 readouts are anticipated for litifilimab in cutaneous lupus erythematosus (CLE) and felzartamab in antibody-mediated rejection during the first half of 2027, followed by zorevunersen in Dravet syndrome in the third quarter of 2027. These catalysts represent a multi-year data flow that management frames as central to the company's next phase of growth.

Investors should also monitor the trajectory of LEQEMBI uptake, the normalization of SPINRAZA's high-dose conversion tailwind, and the company's ability to stabilize the multiple sclerosis business. Rising research and development expenses, combined with a net debt position of roughly $6.4 billion, remain factors worth tracking as Biogen balances pipeline investment against profitability.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations